# Safety and Effectiveness of the Orsiro Sirolimus Eluting Coronary Stent System in Subjects With Coronary Artery Lesions

Study · id `cardio:ct-nct02389946` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02389946](<https://clinicaltrials.gov/study/NCT02389946>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02389946

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1334 participants.

## Technical summary

Registry record NCT02389946. Randomized; single masking; primary purpose treatment. Start 2015-05 (registry gives no type); primary completion 2017-04 (actual). Results posted on 2019-08-01.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 1334 participants (enrolled count; ClinicalTrials.gov record NCT02389946, source copy `cardio:ctgov-nct02389946-2022-08-03`, retrieved 2026-10-26)
- Start date: 2015-05 (registry gives no type) (ClinicalTrials.gov record NCT02389946, source copy `cardio:ctgov-nct02389946-2022-08-03`, retrieved 2026-10-26)
- Primary completion: 2017-04 (actual) (ClinicalTrials.gov record NCT02389946, source copy `cardio:ctgov-nct02389946-2022-08-03`, retrieved 2026-10-26)
- Completion: 2021-03 (actual) (ClinicalTrials.gov record NCT02389946, source copy `cardio:ctgov-nct02389946-2022-08-03`, retrieved 2026-10-26)
- Results first posted: 2019-08-01 (ClinicalTrials.gov record NCT02389946, source copy `cardio:ctgov-nct02389946-2022-08-03`, retrieved 2026-10-26)
- Countries: United States; Australia; Belgium; Canada; Denmark; Germany; Hungary; Israel; Netherlands; New Zealand; South Korea; Spain; Switzerland (ClinicalTrials.gov record NCT02389946, source copy `cardio:ctgov-nct02389946-2022-08-03`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02389946-2022-08-03`, retrieved 2026-10-26)

## The registry's words

- Brief title: Safety and Effectiveness of the Orsiro Sirolimus Eluting Coronary Stent System in Subjects With Coronary Artery Lesions
- Acronym: BIOFLOW-V
- Condition: Coronary Artery Disease
- Condition: Atherosclerosis, Coronary
- Condition: Myocardial Ischemia
- Condition: Ischemic Heart Disease
- Condition: Acute Coronary Syndrome
- Condition: Angina Pectoris
- Intervention (Device): Orsiro DES
- Intervention (Device): Xience DES
- Lead sponsor: Biotronik, Inc.
- Lead sponsor class: INDUSTRY
- Collaborator: Biotronik AG
- Collaborator class: INDUSTRY
- Collaborator: Baim Institute for Clinical Research
- Collaborator class: OTHER
- Collaborator: Medstar Health Research Institute
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Acute coronary syndrome (`cardio:acute-coronary-syndrome`)
- Registry condition terms include this condition: Angina pectoris (`cardio:angina-pectoris`)
- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry lists this organization as the lead sponsor: Biotronik, Inc. (`cardio:org-biotronik-inc`)
- Registry lists this organization as a collaborator: Biotronik AG (`cardio:org-biotronik-ag`)
- Registry lists this organization as a collaborator: Baim Institute for Clinical Research (`cardio:org-baim-institute-for-clinical-research`)
- Registry lists this organization as a collaborator: Medstar Health Research Institute (`cardio:org-medstar-health-research-institute`)

### Main results

- Registry lists this paper as a reference of type result; PubMed types it as a trial report that names this trial and no other, dated on or after the trial start, and its title marks no secondary, follow-up or other further analysis: Ultrathin, bioresorbable polymer sirolimus-eluting stents versus thin, durable polymer everolimus-eluting stents in patients undergoing coronary revascularisation (BIOFLOW V): a randomised trial (`cardio:pubmed-28851504`)

### Other papers using this trial's data

- Registry lists this paper as a reference of type result; PubMed dates it on or after the trial start and types it as a trial report, neither its types nor its title mark it as a protocol, a review or a comment, the paper names no other trial in place of this one, and PubMed shows no retraction or expression of concern; it is not marked as the trial's main report: Ultrathin Bioresorbable Polymer Sirolimus-Eluting Stents Versus Thin Durable Polymer Everolimus-Eluting Stents (`cardio:pubmed-30257191`)
- Registry lists this paper as a reference of type result; PubMed dates it on or after the trial start and types it as a trial report, neither its types nor its title mark it as a protocol, a review or a comment, the paper names no other trial in place of this one, and PubMed shows no retraction or expression of concern; it is not marked as the trial's main report: Subgroup Analysis Comparing Ultrathin, Bioresorbable Polymer Sirolimus-Eluting Stents Versus Thin, Durable Polymer Everolimus-Eluting Stents in Acute Coronary Syndrome Patients (`cardio:pubmed-30354631`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Ultrathin Bioresorbable-Polymer Sirolimus-Eluting Stents Versus Thin Durable-Polymer Everolimus-Eluting Stents for Coronary Revascularization: 3-Year Outcomes From the Randomized BIOFLOW V Trial (`cardio:pubmed-32499026`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: a1254e491d3fe88679aff21e86043db11abb2e6aa252681085d075100369afdb
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
